Who, what , where, when, how?
Who: Patient factors
What: disease factors
Where extent of disease:
When: timing of treatment
How: details of treatment, monitoring, short term and long term side effects, surveillance
-
Type 1 inhibitors good against TKD and ITD FLT3 ( ITD is the one associated with shorter DOR and higher relapse rates) Type 2 ( quizartinib ...
-
Frontline is platinum based chemo with or without bev. G ermline BRCA or HRD, negative - - Observation is ok, Niraparib cat 2A based on ...
-
1. Tafasitamab - CD 19 Ab: approved with lenalidomide for patients with R/R DLBCL ineligible for ASCT. median OS 3 yr. 2L, ineligible for...
No comments:
Post a Comment